Brand Name
Brinsupri
Generic Name
Brensocatib
View Brand Information FDA approval date: August 12, 2025
Form: Tablet
What is Brinsupri (Brensocatib)?
BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis in adult and pediatric patients 12 years of age and older. BRINSUPRI is a dipeptidyl peptidase 1 inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis in adult and pediatric patients 12 years of age and older.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment